Is Kanger International Bhd set to be on par with Careplus Group Bhd in terms of trading volume and share price jump?

Trading volume in Careplus surged amid Covid-19 continuing to spread across the globe, with cases impacting almost every continent.

In March, trading volume in Careplus’ shares jumped, making it one of the top active counters, with five million shares done. The share price in March had been hovering around 27.5 sen to 29 sen.


Careplus is currently trading in the RM3.50 region. It did almost reach RM6.00 about two months ago until Russia announced that it found a cure for the Covid-19 diseases.

The New Straits Times reported today that Kanger aims to build its business with Chinese firms involved in the medical field and bamboo processing.

The newspaper quoted Kanger executive director Steven Kuah who said that top in the list is to distribute the Covid-19 vaccine in Malaysia soon, and regionally from early next year.

Our Foreign Affairs Minister Hishammuddin Hussein during a joint news conference with his Chinese counterpart Wang Yi said today that China has agreed to include Malaysia on a list of priority recipients for a Covid-19 vaccine once it is successfully developed.

Hishammuddin said the Malaysian government is closely monitoring the development of the vaccine and said getting the vaccine is a matter of high priority for the government.

“If we want to find a way forward in dealing with Covid-19 there are only two ways into it, one is to prevent by vaccination, the other is to cure by medication,” he said.

Kanger will benefit greatly from this because it has a tie-up with one of China’s top medical groups which has produced the Covid-19 vaccine and apparently, it works.

According to the NST report, Kanger’s Steven Kuah said this will be a big boost for the pharmaceutical sector, in which the company has a presence in currently.

On September 26, Kanger signed a strategic collaboration agreement with Sinopharm Group Hunan Changde Medical Co Ltd to distribute the vaccine and medical equipment in the Malaysian market.

China National Biotec Group Co Ltd (CNBG), a subsidiary of Sinopharm Group has developed the Covid-19 vaccine called Vero Cell.

It seems Vero Cell has done some testing and it appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials.

Sinopharm is testing the vaccine in more than 10 countries, which includes the United Arab Emirates in a Phase 3 trial.

 Kanger had said it is ready to fund the venture. It has proposed a capital raising exercise and hopes to raise close to RM69 million. 
  According to a Bursa Malaysia filing, Kanger said it intends to pursue business expansion or future viable investment into the healthcare industry.

Kanger may also expand via mergers and acquisitions, joint ventures, collaborative arrangements, business agreements in the healthcare sector.

The exercise involves the issuance of up tmo 20 per cent of the total number of issued shares of the group at an indicative issue price of 17.8 sen per placement share.

As at October 1, 2020, the total issued share capital of Kanger was RM157.83 million comprising 1.832 million shares. 

Kanger said it will use up to RM34 million of the proceeds for future investment, and around RM34.4 million for working capital to expand its existing business.

The stock rose from 18 sen today to 21.5 with high trading volume.

Leave a Reply